Enliven Therapeutics, Inc. · NASDAQ:ELVN
Venrock Healthcare Capital Partners III, L.P. reported a 5.40% stake in Enliven Therapeutics, Inc. (Schedule 13G/A)
Event Sep 30, 2025 · Filed Nov 14, 2025
Venrock Healthcare Capital Partners III, L.P. reported a 5.40% stake in Enliven Therapeutics, Inc., 3,226,331 shares, as a passive investor on Sep 30, 2025. Filed Nov 14, 2025 (Schedule 13G/A).
- Stake
- 5.40%
- Shares
- 3,226,331
- Intent
- Passive
- What changed
- Stake changed
- Filed together
- 7 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Venrock Healthcare Capital Partners III, L.P. | 5.40% | 3,226,331 |
| VHCP Co-Investment Holdings III, LLC | 5.40% | 3,226,331 |
| Venrock Healthcare Capital Partners EG, L.P. | 5.40% | 3,226,331 |
| VHCP Management III, LLC | 5.40% | 3,226,331 |
| VHCP Management EG, LLC | 5.40% | 3,226,331 |
| Nimish Shah | 5.40% | 3,226,331 |
| Bong Y. Koh | 5.40% | 3,226,331 |
Source
Related
- Enliven Therapeutics, Inc.
- Venrock Healthcare Capital Partners III, L.P.
- Enliven Therapeutics, Inc. shareholders
- Schedule 13G/A · Venrock Healthcare Capital Partners III, L.P. · May 15, 2026
- Form 4 · Hohl Benjamin · Oct 21, 2026
- Form 4 · Collins Helen Louise · Oct 21, 2026
- Form 4 · Garland J. Scott · Oct 5, 2026
- Form 4 · Hohl Benjamin · Sep 21, 2026
- Form 4 · Collins Helen Louise · Sep 21, 2026